A Mini Review of Doose Syndrome: Clinical Manifestations, Diagnosis, and Treatment

Authors

DOI:

https://doi.org/10.80481/revuetest39024

Keywords:

Doose syndrome, Myoclonic-astatic epilepsy, Antiepileptic drugs, Corticosteroids, Corpus callosotomy, cannabidiol

Abstract

Doose syndrome, or myoclonic-astatic epilepsy (MAE), is a rare and complex epileptic encephalopathy that affects young children. Characterized by myoclonic-atonic seizures, generalized tonic-clonic seizures, and atypical absence seizures, the etiology of Doose syndrome is heterogeneous and involves both genetic and environmental factors. While advancements in genetic research have contributed to a better understanding of the syndrome, no major genetic factor has been identified, highlighting the need for further investigation. Diagnosis relies on thorough clinical evaluation, electroencephalographic findings, and, in some cases, genetic testing. Early diagnosis is critical, as certain antiepileptic drugs may exacerbate the condition, while others can provide better seizure control. Treatment options include medications such as valproate, levetiracetam, and lamotrigine, ketogenic and modified Atkins diets, corticosteroids, and, in refractory cases, corpus callosotomy. Recent studies have also shown promise in using highly purified cannabidiol for the treatment of refractory epilepsy in Doose syndrome. Future research should focus on elucidating the genetic and environmental factors involved in the development and progression of Doose syndrome and identifying novel therapeutic targets. Additionally, further investigation of existing treatment options, including dietary therapies and highly purified cannabidiol, is necessary to optimize patient care and improve long-term prognosis for individuals affected by this rare and challenging epilepsy syndrome.

Author Biography

Mohamed AHAKOUD, sidi mohamed ben abdellah university

Genetic

References

Kelley SA, Kossoff EH: Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010, 52:988–93. 10.1111/j.1469-8749.2010.03744.x

Dubru JM, Bricteux G, Panagopoulos A, Makanda A, Klein JM: [Clinical case of the month. Myoclonic-astatic epilepsy in a young child (MAE) or Doose syndrome]. Rev Med Liege. 2002, 57:191–5.

Inoue T, Ihara Y, Tomonoh Y, et al.: Early onset and focal spike discharges as indicators of poor prognosis for myoclonic-astatic epilepsy. Brain Dev. 2014, 36:613–9. 10.1016/j.braindev.2013.08.009

Tang S, Pal DK: Dissecting the genetic basis of myoclonic-astatic epilepsy. Epilepsia. 2012, 53:1303–13. 10.1111/j.1528-1167.2012.03581.x

Nickels K, Kossoff EH, Eschbach K, Joshi C: Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort. Epilepsia. 2021, 62:120–7. 10.1111/epi.16752

Moeller F, Groening K, Moehring J, et al.: EEG-fMRI in myoclonic astatic epilepsy (Doose syndrome). Neurology. 2014, 82:1508–13. 10.1212/WNL.0000000000000359

You SJ, Jung DE, Kim HD, Lee HS, Kang H-C: Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2008, 12:314–20. 10.1016/j.ejpn.2007.09.003

Stenger E, Schaeffer M, Cances C, et al.: Efficacy of a ketogenic diet in resistant myoclono-astatic epilepsy: A French multicenter retrospective study. Epilepsy Res. 2017, 131:64–9. 10.1016/j.eplepsyres.2017.02.005

Zavala-Yoe R, Ramirez-Mendoza RA, Cordero LM: Entropy measures to study and model long term simultaneous evolution of children in Doose and Lennox-Gastaut syndromes. J Integr Neurosci. 2016, 15:205–21. 10.1142/S0219635216500138

Trivisano M, Striano P, Sartorelli J, et al.: CHD2 mutations are a rare cause of generalized epilepsy with myoclonic-atonic seizures. Epilepsy Behav EB. 2015, 51:53–6. 10.1016/j.yebeh.2015.06.029

Oguni H: Epilepsy with myoclonic-atonic seizures, also known as Doose syndrome: Modification of the diagnostic criteria. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2022, 36:37–50. 10.1016/j.ejpn.2021.11.009

Vlaskamp DRM, Rump P, Callenbach PMC, Vos YJ, Sikkema-Raddatz B, van Ravenswaaij-Arts CMA, Brouwer OF: Haploinsufficiency of the STX1B gene is associated with myoclonic astatic epilepsy. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2016, 20:489–92. 10.1016/j.ejpn.2015.12.014

Doege C, May TW, Siniatchkin M, von Spiczak S, Stephani U, Boor R: Myoclonic astatic epilepsy (Doose syndrome) - a lamotrigine responsive epilepsy? Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2013, 17:29–35. 10.1016/j.ejpn.2012.10.006

Press CA, Knupp KG, Chapman KE: Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav EB. 2015, 45:49–52. 10.1016/j.yebeh.2015.02.043

Wiemer-Kruel A, Haberlandt E, Hartmann H, Wohlrab G, Bast T: Modified Atkins diet is an effective treatment for children with Doose syndrome. Epilepsia. 2017, 58:657–62. 10.1111/epi.13701

Simard-Tremblay E, Berry P, Owens A, et al.: High-fat diets and seizure control in myoclonic-astatic epilepsy: a single center’s experience. Seizure. 2015, 25:184–6. 10.1016/j.seizure.2014.10.009

Nickels K, Thibert R, Rau S, et al.: How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey. Epilepsy Res. 2018, 144:14–9. 10.1016/j.eplepsyres.2018.04.010

Kanai S, Okanishi T, Nishimura M, et al.: Successful corpus callosotomy for Doose syndrome. Brain Dev. 2017, 39:882–5. 10.1016/j.braindev.2017.06.001

Stephani U: The natural history of myoclonic astatic epilepsy (Doose syndrome) and Lennox-Gastaut syndrome. Epilepsia. 2006, 47 Suppl 2:53–5. 10.1111/j.1528-1167.2006.00690.x

Yordanova I, Todorov T, Dimova P, et al.: One novel Dravet syndrome causing mutation and one recurrent MAE causing mutation in SCN1A gene. Neurosci Lett. 2011, 494:180–3. 10.1016/j.neulet.2011.03.008

Palmer S, Towne MC, Pearl PL, et al.: SLC6A1 Mutation and Ketogenic Diet in Epilepsy With Myoclonic-Atonic Seizures. Pediatr Neurol. 2016, 64:77–9. 10.1016/j.pediatrneurol.2016.07.012

Liu J, Tong L, Song S, et al.: Novel and de novo mutations in pediatric refractory epilepsy. Mol Brain. 2018, 11:48. 10.1186/s13041-018-0392-5

Nieto Barrera M, Candau Fernandez Mensaque R, Nieto Jiménez M: [Severe myoclonic epilepsy in infancy (Dravet’s syndrome). Its nosological characteristics and therapeutic aspects]. Rev Neurol. 2003, 37:64–8.

Downloads

Published

03-05-2023

Issue

Section

Articles